Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

therapy of dermatological diseases," said Robert Booth .

Background

About Cathepsin S and VBY-036

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes proteolytic cleavage of membrane-bound fractalkine from the surface of neurons to release soluble fractalkine.  Fractalkine is a potent chemokine that stimulates the recruitment of inflammatory cells to the sites of neuronal damage and activates microglia.  Microglia are macrophage-like cells that are implicated as key drivers in the pathogenesis of chronic neuropathic pain syndromes.  In model systems, cathepsin S mediated microglial activation is essential in the development of pain.  The inhibition of cathepsin S results in a reduction in pain, as well as prevention of pain in preclinical models of chemotherapy-induced neuropathic pain and diabetic neuropathy.

VBY-036 is an optimized cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of cathepsin S.  It has picomolar inhibitory potency against the isolated cathepsin S enzyme and nanomolar activity in cellular assays.  VBY-036 is also highly selective against related human cathepsins as well as other enzymes, and sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker.  The compound has been tested in pre-clinical studies and is now entering the next phase - a phase 1 clinical trial in healthy human volunteers.  The VBY-036 program is a novel approach to the treatment of pain and may result in a safe and effective oral therapeutic for an important unmet medical need.  

About Virobay, Inc.

Founded in 2006, Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a class of enzymes that are key mediators in a variety of diseases, including autoimmunity, neuropath
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Athena ... personal development of executive women in San Diego’s technology ... the 17th Annual Pinnacle Awards at their Gala on ... Hyatt Hotel. Register now at http://athenasd.org/events/ , ... support the Athena San Diego vision of fostering networking, ...
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... report its first quarter 2015 results before the Nasdaq ... then host a live conference call and webcast to discuss ... morning, April 30, 2015 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1906 (US) or ...
(Date:4/23/2015)... Prospects for Leading Companies in ... Details   We predict the global healthcare ... in 2015 and will grow at a CAGR of 6.3% ... around the world and increasing functional requirements for healthcare packaging ... global healthcare packaging market. A global ageing population, ...
(Date:4/23/2015)... April 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC ... Overview ® (EIO) on Aeterna Zentaris Inc. (NASDAQ: ... available on Crystal Research Associates, website at ... website at www.aezsinc.com . Aeterna Zentaris ... biopharmaceutical company in oncology, endocrinology, and women,s health. With ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3
... Sept. 19 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... Administration,s Office of Orphan Products Development has granted,orphan ... for,injection) for the treatment of hypoparathyroidism, a rare ... FDA-approved therapy. Hypoparathyroidism afflicts approximately 65,000 people ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company ... it is scheduled to present,at the 2007 UBS Global ... President and Chief Executive Officer, and Jeffery,Tobias, Chief Medical ... September 25, 2007 Time: 9:00 a.m. ...
... Sept. 19 The Pittsburgh Life Sciences,Greenhouse ... life,sciences industry on a fast track for ... in Coventina Healthcare Enterprises, Inc., a medical,device ... Frequency),and multi-modal treatment systems for research, rehabilitation, ...
Cached Biology Technology:PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 2PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 3NeurogesX to Present at UBS 2007 Global Life Sciences Conference 2NeurogesX to Present at UBS 2007 Global Life Sciences Conference 3The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 2The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh 3
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... New research in The FASEB Journal suggests that rats ... and increased appetite and muscle mass, as well as the number ... are looking to lean out, add muscle mass, and get ripped, ... ( http://www.fasebj.org ) suggests that you might want to look to ...
... Species, ability to overcome adversity goes beyond Darwin,s survival of ... a new study based on simulations examining species and their ... animal can make it to a final, climate-friendly destination isn,t ... way. It,s the extent to which the creatures can withstand ...
... endangered, but their long lives and broad distribution make ... level to different populations and devise appropriate conservation strategies. ... method to evaluate spatially and biologically distinct groups of ... identify threats and data gaps at different scales. ...
Cached Biology News:Lift weights, eat mustard, build muscles? 2Climate change will show which animals can take the heat 2Climate change will show which animals can take the heat 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Ms anti-Cyclophilin D...
... Intended to qualitatively detect ... formalin-fixed, paraffin-embedded (FFPE) tissue ... and cell preparations, using ... (CISH). Fluorescent In Situ ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Biology Products: